Spiro Gavaris is the President, Specialty Generics, at Mallinckrodt Pharmaceuticals. He has responsibility for the company’s specialty generics, active pharmaceutical ingredients and non-promoted brands products, and is a member of Mallinckrodt’s senior leadership team.
Previously, Spiro served as president of the U.S. Injectables division of Hikma. Spiro also served as a practice executive at Campbell Alliance consulting firm, working with pharmaceutical, biotech, animal health and device companies. He entered the pharmaceuticals industry in sales for Bristol Myers-Squib after working as a civil engineer.
Spiro holds a bachelor’s degree from Franklin and Marshall College and an MBA in marketing and management from New York University, Stern School of Business.